Biosimilars Roundtable

Part One:

Topics covered: Disclosures, introduction of biosimilars, how biosimilars are developed, FDA guidelines, bioequivalence, clinical trials/end points, approval/going to market, extrapolation for cancer subtypes

TRT 18:02

Part Two:

Topics covered: interchangeability, formulation, efficacy, safety, end points, cost,

TRT 18:30

Part Three:

Topics covered: EMA approval, ASCO/NCCN guidelines, reliability

TRT 18:30

Part Four:

Topics covered: pricing, audience Q&A

TRT 15:14